Abstract
Bullous pemphigoid (BP) is an autoimmune blistering disease, characterized by subepidermal blisters and mediated by IgG autoantibodies against BP180 (type XVII collagen) and BP230 structural proteins of the dermal-epidermal junction. Efgartigimod, an engineered Fc fragment, inhibits FcRn activity, thereby decreasing serum IgG and autoantibodies. This pre-registration report describes a Phase 2/3 randomized, double-blind, placebo-controlled trial of efgartigimod in patients with moderate to severe (by PDAI) BP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
